Citi keeps USD 45.00 target for Zai Lab stock

Published on 10/20/2026 at 21:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 106.31 million. Zai Lab stock costs EUR 22.30 on October 20, 2026, up 6.19 percent versus the Frankfurt close.

Analyst target and reporting date

Citi maintained a USD 45.00 target and Buy rating for Zai Lab on October 19, 2026.
Second-quarter revenue reached USD 106.31 million, while net income was negative USD 50.83 million.
Zai Lab stock costs EUR 22.30 at Lang & Schwarz on October 20, 2026 at 9:05 p.m. CEST, 6.19 percent above the Frankfurt close of October 19, 2026.
Initial ZL-1503 trial findings are scheduled for November 13, 2026.

ZLAB, US98887Q1040, Illustration mit AI erstellt.

Zai Lab Limited (US98887Q1040) held a Buy rating and a USD 45.00 price target from Citi on October 19, 2026, according to Business Insider. The company stock was trading at EUR 22.30 at Lang & Schwarz on October 20, 2026 at 9:05 p.m. CEST, up 6.19 percent versus the Frankfurt close of October 19, 2026 at EUR 21.00.

Revenue reached USD 106.31 million

Zai Lab reported USD 106.31 million in revenue for the second quarter of 2026. Net income was negative USD 50.83 million for the same period, according to Business Quant. The result gives investors two separate signals: commercial revenue has reached a material quarterly scale, while profitability remains negative.

Stock remains below its yearly high

The Nasdaq-listed stock was last quoted at USD 25.15 on October 20, 2026 at 3:07 p.m. ET. Its 52-week range was USD 15.96 to USD 29.77, leaving the quote 15.52 percent below the high and 57.58 percent above the low. Market capitalization stood at USD 2.8 billion, while reported volume was 593,145 shares.

What comes next for the pipeline?

Zai Lab's investor-relations page identifies Nasdaq ticker ZLAB and describes the company as a commercial-stage biopharmaceutical group focused on oncology, immunology, neuroscience and infectious diseases. Its initial Phase 1/1b findings for the ZL-1503 atopic dermatitis program are scheduled for November 13, 2026, as reported by Sept Investing. The date gives the pipeline a defined near-term event, while Citi's USD 45.00 target remains the clearest external valuation marker.

Price and valuation in view

The USD 25.15 Nasdaq quote was 44.89 percent below Citi's USD 45.00 target on October 19, 2026. Zai Lab also reported a negative price-to-earnings ratio of 13.79 and no trailing dividend yield, placing the focus on clinical progress and revenue execution rather than current distributions.

Trading level and next catalyst

At EUR 22.30, the Lang & Schwarz quote was 6.19 percent above the Frankfurt close of EUR 21.00 dated October 19, 2026. The next dated company event is the November 13, 2026 presentation of initial ZL-1503 trial findings.

The further course of trading is shown by the continuously updated real-time quote of Zai Lab stock.